Screening for Prostate Cancer 300 Times More Sensitive Than Current Tests
Screening breakthrough detects PSA levels that other tests read as zero, and could provide men who had their prostates removed but still have cancer with safer, earlier treatments.
Interview With Fred Robertson, President & CEO of TomoTherapy
TomoTherapy president and CEO Fred Robertson talks with DOTmed about his perspective on ASTRO's 2009 annual meeting, changes in the radiation oncology industry and two important TomoTherapy product launches that occurred at the show. Watch the HD video.
Need to ship this item?
Use DOTmed's Shipping Quote Service!
Get Started!
xray with collimator and stand, in great working condition.